newsfilter
← Latest News
GlobeNewswire·

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

Objective Response Rate (ORR) by Central Review Achieved in Each Cohort at Interim Efficacy Analysis that Exceeded the Futility Threshold Enrollment Continues Ahead of Schedule; Next Interim Analysis Expected in